Triple-negative breast cancer: Are we making headway at least?

Therapeutic Advances in Medical Oncology

Volumn 4, Issue 4, 2012, Pages 195-210

  Arnedos, Monica ^a   Bihan, Celine ^a   Delaloge, Suzette ^a   Andre, Fabrice ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

basal like; BRCA1; breast cancer; PARP; poly(ADP ribose) polymerase inhibitors; triple negative

Indexed keywords

8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; ALKYLATING AGENT; ANTHRACYCLINE DERIVATIVE; BEVACIZUMAB; CAPECITABINE; CEDIRANIB; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ENTINOSTAT; EPIRUBICIN; ERLOTINIB; EVEROLIMUS; FLUOROURACIL; INIPARIB; IXABEPILONE; N (6,7 DIHYDRO 6 OXO 5H DIBENZ[B,D]AZEPIN 7 YL) 2,2 DIMETHYL N' (2,2,3,3,3 PENTAFLUOROPROPYL)PROPANEDIAMIDE; OLAPARIB; ONARTUZUMAB; PACLITAXEL; PANITUMUMAB; ROSCOVITINE; SORAFENIB; SUNITINIB; TAXANE DERIVATIVE; TIGATUZUMAB; TRABECTEDIN; UNINDEXED DRUG; VELIPARIB;

AGE DISTRIBUTION; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; DIARRHEA; DISEASE COURSE; DISEASE FREE SURVIVAL; DISTANT METASTASIS; DRUG MECHANISM; EXCISION REPAIR; G2 PHASE CELL CYCLE CHECKPOINT; HAND FOOT SYNDROME; HUMAN; INFECTION; LIFE EXPECTANCY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POST TREATMENT SURVIVAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE FREE SURVIVAL; RECURRENCE RISK; REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; UNSPECIFIED SIDE EFFECT; VISCERAL METASTASIS;

EID: 84866866082     PISSN: 17588340     EISSN: 17588359     Source Type: Journal    
DOI: 10.1177/1758834012444711     Document Type: Review

References (96)

1. Adis R&D Profile (2006) Trabectedin: Ecteinascidin 743, Ecteinascidin-743, ET 743, ET-743, NSC 684766. Drugs R D 7: 317–328.
2. Andre F. Delaloge S. Soria J.C. (2011) Biology-driven phase II trials: what is the optimal model for molecular selection? J Clin Oncol 29: 1236–1238.
3. Andre F. Job B. Dessen P. Tordai A. Michiels S. Liedtke C. et al. (2009) Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array. Clin Cancer Res 15: 441–451.
4. Arnedos M. de La Cruz J. Job B. Scott V. Dessen P. Gentien D. et al. (2011) High throughput molecular analyses to select patients for targeted agents. Eur J Cancer 47(Suppl. 1): S95.
5. Ashwell S. Janetka J.W. Zabludoff S. (2008) Keeping checkpoint kinases in line: new selective inhibitors in clinical trials. Expert Opin Investig Drugs 17: 1331–1340.
6. Ashwell S. Zabludoff S. (2008) DNA damage detection and repair pathways–recent advances with inhibitors of checkpoint kinases in cancer therapy. Clin Cancer Res 14: 4032–4037.
7. Azoulay S. Lae M. Freneaux P. Merle S. Al Ghuzlan A. Chnecker C. et al. (2005) KIT is highly expressed in adenoid cystic carcinoma of the breast, a basal-like carcinoma associated with a favorable outcome. Mod Pathol 18: 1623–1631.
8. Barrios C. Liu M.C. Lee S.C. Vanlemmens L. Ferrero J.M. Tabei T. et al. (2009) Phase III randomized trial of sunitinib (SU) vs. capecitabine (C) in patients (Pts) with previously treated HER2-negative advanced breast cancer (ABC). In San Antonio Breast Cancer Symposium, abstract 46.
9. Baselga J. Gomez P. Awada A. Greil R. Braga S. Climent M. et al. (2010) The addition of cetuximab to cisplatin increases overall response rate (ORR) and progression-free survival (PFS) in metastatic triple-negative breast cancer (TNBC): results of a randomized phase II study (BALI-1). Ann Oncol 21(Suppl.): abstract 274.
10. Baselga J., Grupo Español de Estudio Tratamiento y Otras Estrategias Experimentales en Tumores Sólidos, Roché H. Costa F. Getúlio Martins Segalla J. Pinczowski et al. (2009) SOLTI-0701: a multinational double-blind, randomized phase 2b study evaluating the efficacy and safety of sorafenib compared to placebo when administered in combination with capecitabine in patients with locally advanced or metastatic breast cancer (BC). In San Antonio Breast Cancer Symposium, abstract 45.
11. Bauer K.R. Brown M. Cress R.D. Parise C.A. Caggiano V. (2007) Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer 109: 1721–1728.
12. Bear H.D. Tang G. Rastogi P. Geyer C.E. Jr Robidoux A. Atkins J.N. et al. (2012) Bevacizumab added to neoadjuvant chemotherapy for breast cancer. N Engl J Med 366: 310–320.
13. Beuvink I. Boulay A. Fumagalli S. Zilbermann F. Ruetz S. O'Reilly T. et al. (2005) The mTOR inhibitor RAD 001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p 21 translation. Cell 120: 747–759.
14. Bolderson E. Richard D.J. Zhou B.B. Khanna K.K. (2009) Recent advances in cancer therapy targeting proteins involved in DNA double-strand break repair. Clin Cancer Res 15: 6314–6320.
15. Bostrom P. Soderstrom M. Palokangas T. Vahlberg T. Collan Y. Carpen O. et al. (2009) Analysis of cyclins A, B1, D 1 and E in breast cancer in relation to tumour grade and other prognostic factors. BMC Res Notes 2: 140.
16. Brufsky A. Bondarenko I.N. Smirnov V. Hurvitz S. Perez E. Ponomarova O. et al. (2009) RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of HER2-negative metastatic breast cancer. Cancer Res 69(24(Suppl. 1)): abstract 42.
17. Burstein H.J. Elias A.D. Rugo H.S. Cobleigh M.A. Wolff A.C. Eisenberg P.D. et al. (2008) Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 26: 1810–1817.
18. Byrski T. Gronwald J. Huzarski T. Grzybowska E. Budryk M. Stawicka M. et al. (2010) Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol 28: 375–380.
19. Carey L.A. Dees E.C. Sawyer L. Gatti L. Moore D.T. Collichio F. et al. (2007) The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 13: 2329–2334.
20. Cheang M. Chia S.K. Tu D. Jiang S. Shepherd L.E. Pritchard K.I. et al. (2009) Anthracyclines in basal breast cancer: The NCIC-CTG trial MA 5 comparing adjuvant CMF to CEF. J Clin Oncol 27(15 Suppl.): a519.
21. Cheang M.C. Voduc D. Bajdik C. Leung S. McKinney S. Chia S.K. et al. (2008) Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 14: 1368–1376.
22. Dent R. Hanna W.M. Trudeau M. Rawlinson E. Sun P. Narod S.A. (2009) Pattern of metastatic spread in triple-negative breast cancer. Breast Cancer Res Treat 115: 423–428.
23. Dent R. Trudeau M. Pritchard K.I. Hanna W.M. Kahn H.K. Sawka C.A. et al. (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13: 4429–4434.
24. Dent R.A. Lindeman G.J. Clemons M. Wildiers H. Chan A. McCarthy N.J. et al. (2010) Safety and efficacy of the oral PARP inhibitor olaparib (AZD2281) in combination with paclitaxel for the first- or second-line treatment of patients with metastatic triple-negative breast cancer: Results from the safety cohort of a phase I / II multicenter trial. J Clin Oncol 28(15 Suppl.): abstract 1018.
25. Doane A.S. Danso M. Lal P. Donaton M. Zhang L. Hudis C. et al. (2006) An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene 25: 3994–4008.
26. Falo C. Moreno A. Varela M. Lloveras B. Figueras A. Escobedo A. (2007) HER-2/neu status and response to CMF: retrospective study in a series of operable breast cancer treated with primary CMF chemotherapy. J Cancer Res Clin Oncol 133: 423–429.
27. Farmer H. McCabe N. Lord C.J. Tutt A.N. Johnson D.A. Richardson T.B. et al. (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434: 917–921.
28. Finn R.S. Dering J. Ginther C. Wilson C.A. Glaspy P. Tchekmedyian N. et al. (2007) Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/“triple-negative” breast cancer cell lines growing in vitro. Breast Cancer Res Treat 105: 319–326.
29. Gelmon K. Chan A. Harbeck N. (2006) The role of capecitabine in first-line treatment for patients with metastatic breast cancer. Oncologist 11(Suppl. 1): 42–51.
30. Gelmon K.A. Hirte H.W. Robidoux A. Tonkin K.S. Tischkowitz M. Swenerton K. et al. (2010) Can we define tumors that will respond to PARP inhibitors? A phase II correlative study of olaparib in advanced serous ovarian cancer and triple-negative breast cancer. J Clin Oncol 28(15 Suppl.): abstract 3002.
31. Gennari A. Sormani M.P. Pronzato P. Puntoni M. Colozza M. Pfeffer U. et al. (2008) HER 2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials. J Natl Cancer Inst 100: 14–20.
32. Geyer F.C. Lacroix-Triki M. Savage K. Arnedos M. Lambros M.B. MacKay A. et al. (2011) beta-Catenin pathway activation in breast cancer is associated with triple-negative phenotype but not with CTNNB 1 mutation. Mod Pathol 24: 209–231.
33. Gradishar W.J. Kaklamani V. Prasad Sahoo T. Lokanatha D. Raina V. Bondarde S. et al. (2009) A double-blind, randomized, placebo-controlled, phase 2b study evaluating the efficacy and safety of sorafenib (SOR) in combination with paclitaxel (PAC) as a first-line therapy in patients (pts) with locally recurrent or metastatic breast cancer (BC). Cancer Res 69(24 Suppl. 1): abstract 44.
34. Gurtler J.S. Goldstein L. Delprete S. Tjulandin S. Semiglazov V. Sternas L. et al. (2005) Trabectedin in third line breast cancer: A multicenter, randomized, phase II study comparing two administration regimens. J Clin Oncol 23(16 Suppl.): 625.
35. Hayes D.F. Thor A.D. Dressler L.G. Weaver D. Edgerton S. Cowan D. et al. (2007) HER 2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 357: 1496–1506.
36. Hiscox S. Morgan L. Green T.P. Barrow D. Gee J. Nicholson R.I. (2006) Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells. Breast Cancer Res Treat 97: 263–274.
37. Hugh J. Hanson J. Cheang M.C. Nielsen T.O. Perou C.M. Dumontet C. et al. (2009) Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol 27: 1168–1176.
38. Huober J. von Minckwitz G. Denkert C. Tesch H. Weiss E. Zahm D.M. et al. (2010) Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study. Breast Cancer Res Treat 124: 133–140.
39. Isakoff S.J. Overmoyer B. Tung N.M. Gelman R.S. Giranda V.L. Bernhard K.M. et al. (2010) A phase II trial of the PARP inhibitor veliparib (ABT888) and temozolomide for metastatic breast cancer. J Clin Oncol 28(15 Suppl.) abstract 1019.
40. Joensuu H. Hemminki A. Huovinen R. Tanner M. Kokko R. Asola R. et al. (2007) The FinXX trial: Safety results in 600 patients (pts) randomized to either docetaxel (T) followed by cyclophosphamide (C) + epirubicin (E) + 5-FU (F) (CEF) or T + capecitabine (X) followed by CEX as adjuvant therapy for early breast cancer (BC). J Clin Oncol 25(18 Suppl.): 11035.
41. Joensuu H. Kellokumpu-Lehtinen P.L. Huovinen R. Jukkola-Vuorinen A. Tanner M. Kokko R. et al. (2010) FinXX final 5-year analysis: results of the randomised, open-label, phase III trial in medium-to-high risk early breast cancer. In San Antonio Breast Cancer Symposium, abstract S4–1.
42. Jones C. Mackay A. Grigoriadis A. Cossu A. Reis-Filho J.S. Fulford L. et al. (2004) Expression profiling of purified normal human luminal and myoepithelial breast cells: identification of novel prognostic markers for breast cancer. Cancer Res 64: 3037–3045.
43. Kimbung S. Biskup E. Johansson I. Aaltonen K. Ottosson-Wadlund A. Gruvberger-Saal S. et al. (2012) Co-targeting of the PI3K pathway improves the response of BRCA 1 deficient breast cancer cells to PARP 1 inhibition. Cancer Lett, in press.
44. Kopetz S. Mita M.M. Mok I. Sankhala K.K. Moseley J. Sherman B.M. et al. (2008) First in human phase I study of BSI-201, a small molecule inhibitor of poly ADP-ribose polymerase (PARP) in subjects with advanced solid tumors. J Clin Oncol 26(Suppl.): abstract 3577.
45. Lae M. Freneaux P. Sastre-Garau X. Chouchane O. Sigal-Zafrani B. Vincent-Salomon A. (2009) Secretory breast carcinomas with ETV6-NTRK3 fusion gene belong to the basal-like carcinoma spectrum. Mod Pathol 22: 291–298.
46. Lehmann-Che J. Andre F. Desmedt C. Mazouni C. Giacchetti S. Turpin E. et al. (2010) Cyclophosphamide dose intensification may circumvent anthracycline resistance of p 53 mutant breast cancers. Oncologist 15: 246–252.
47. Lehmann B.D. Bauer J.A. Chen X. Sanders M.E. Chakravarthy A.B. Shyr Y. et al. (2011) Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 121: 2750–2767.
48. Liedtke C. Mazouni C. Hess K.R. Andre F. Tordai A. Mejia J.A. et al. (2008) Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 26: 1275–1281.
49. Lin N.U. Claus E. Sohl J. Razzak A.R. Arnaout A. Winer E.P. (2008) Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer 113: 2638–2645.
50. Linderholm B.K. Hellborg H. Johansson U. Elmberger G. Skoog L. Lehtio J. et al. (2009) Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer. Ann Oncol 20: 1639–1646.
51. Liu L.Z. Zhou X.D. Qian G. Shi X. Fang J. Jiang B.H. (2007) AKT 1 amplification regulates cisplatin resistance in human lung cancer cells through the mammalian target of rapamycin/p70S6K1 pathway. Cancer Res 67: 6325–6332.
52. Mabuchi S. Kawase C. Altomare D.A. Morishige K. Sawada K. Hayashi M. et al. (2009) mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary. Clin Cancer Res 15: 5404–5413.
53. Mahany J.J. Lewis N. Heath E.I. LoRusso P.M. Mita M.M. Rodon J. et al. (2008) A phase IB study evaluating BSI-201 in combination with chemotherapy in subjects with advanced solid tumors. J Clin Oncol 26(Suppl.): abstract 3579.
54. Marchio C. Weigelt B. Reis-Filho J.S. (2010) Adenoid cystic carcinomas of the breast and salivary glands (or ‘The strange case of Dr Jekyll and Mr Hyde’ of exocrine gland carcinomas). J Clin Pathol 63: 220–228.
55. Martin M. Segui M.A. Anton A. Ruiz A. Ramos M. Adrover E. et al. (2010) Adjuvant docetaxel for high-risk, node-negative breast cancer. N Engl J Med 363: 2200–2210.
56. Marty B. Maire V. Gravier E. Rigaill G. Vincent-Salomon A. Kappler M. et al. (2008) Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells. Breast Cancer Res 10 (6): R101.
57. Matthews D.J. Yakes F.M. Chen J. Tadano M. Bornheim L. Clary D.O. et al. (2007) Pharmacological abrogation of S-phase checkpoint enhances the anti-tumor activity of gemcitabine in vivo. Cell Cycle 6: 104–110.
58. Miles D.W. Chan A. Dirix L.Y. Cortes J. Pivot X. Tomczak P. et al. (2010) Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 28: 3239–3247.
59. Miller K. Wang M. Gralow J. Dickler M. Cobleigh M. Perez E.A. et al. (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357: 2666–2676.
60. Nielsen T.O. Hsu F.D. Jensen K. Cheang M. Karaca G. Hu Z. et al. (2004) Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10: 5367-5374.
61. Niemeier L.A. Dabbs D.J. Beriwal S. Striebel J.M. Bhargava R. (2010) Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation. Mod Pathol 23: 205–212.
62. O'Shaughnessy J. Dieras V. Glaspy J. Brufsky A. Miller K.D. Miles D.W. et al. (2009) Comparison of subgroup analyses of PFS from three phase III studies of bevacizumab in combination with chemotherapy in patients with HER2-negative metastatic breast cancer (MBC). Cancer Res 69(24 Suppl. 1): abstract 207.
63. O'Shaughnessy J. Osborne C. Pippen J.E. Yoffe M. Patt D. Rocha C. et al. (2011 a) Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med 364: 205–214.
64. O'Shaughnessy J. Paul D. Stokoe C. Pippen J.J. Blum J.L. Krekow L. et al. (2010) First efficacy results of a randomized, open-label, phase III study of adjuvant doxorubicin plus cyclophosphamide, followed by docetaxel with or without capecitabine, in high-risk early breast cancer. In San Antonio Breast Cancer Symposium, abstract S4–2.
65. O'Shaughnessy J. Schwartzberg L.S. Danso M.A. Rugo H.S. Miller K. Yardley D.A. et al. (2011 b) A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine / carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC). J Clin Oncol 29(Suppl.): abstract 1007.
66. O'Shaughnessy J. Weckstein D.J. Vukelja S.J. McIntyre K. Krekow L. Holmes F.A. et al. (2007) Randomized phase II study of weekly irinotecan / carboplatin with or without cetuximab in patients with metastatic breast cancer. Breast Cancer Res Treat 106(32 Suppl. 1): abstract 308.
67. Park S.Y. Lee H.E. Li H. Shipitsin M. Gelman R. Polyak K. (2010) Heterogeneity for stem cell-related markers according to tumor subtype and histologic stage in breast cancer. Clin Cancer Res 16: 876–887.
68. Perez E.A. Patel T. Moreno-Aspitia A. (2010) Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancer. Breast Cancer Res Treat 121: 261–271.
69. Perou C.M. (2011) Molecular stratification of triple-negative breast cancers. Oncologist 16(Suppl. 1): 61–70.
70. Perou C.M. Sorlie T. Eisen M.B. van d.e. Rijn M. Jeffrey S.S. Rees C.A. et al. (2000) Molecular portraits of human breast tumours. Nature 406: 747–752.
71. Pristauz G. Petru E. Stacher E. Geigl J.B. Schwarzbraun T. Tsybrovskyy O. et al. (2010) Androgen receptor expression in breast cancer patients tested for BRCA 1 and BRCA 2 mutations. Histopathology 57: 877–884.
72. Rakha E.A. El-Sayed M.E. Green A.R. Lee A.H. Robertson J.F. Ellis I.O. (2007) Prognostic markers in triple-negative breast cancer. Cancer 109: 25–32.
73. Rakha E.A. Ellis I.O. (2009) Triple-negative/basal-like breast cancer: review. Pathology 41: 40–47.
74. Reid A.H. Attard G. Danila D.C. Oommen N.B. Olmos D. Fong P.C. et al. (2010) Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP 17 inhibitor abiraterone acetate. J Clin Oncol 28: 1489–1495.
75. Robert C. Thomas L. Bondarenko I. O'Day S.M.D.J. Garbe C. et al. (2011) Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364: 2517–2526.
76. Roche H. Fumoleau P. Spielmann M. Canon J.L. Delozier T. Serin D. et al. (2006) Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial. J Clin Oncol 24: 5664–5671.
77. Rouzier R. Perou C.M. Symmans W.F. Ibrahim N. Cristofanilli M. Anderson K. et al. (2005) Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 11: 5678–5685.
78. Rugo H.S. Roche H. Thomas E. Blackwell K. Chung H.C. Lerzo G. et al. (2008) Ixabepilone plus capecitabine vs capecitabine in patients with triple negative tumors: a pooled analysis of patients from two large phase III clinical studies. In San Antonio Breast Cancer Symposium, abstract 3057.
79. Ryan P.D. Tung N.M. Isakoff S.J. Golshan M. Richardson A. Corben A.D. et al. (2009) Neoadjuvant cisplatin and bevacizumab in triple negative breast cancer (TNBC): Safety and efficacy. J Clin Oncol 27(15 Suppl.): abstract 551.
80. Scholl S.M. Pierga J.Y. Asselain B. Beuzeboc P. Dorval T. Garcia-Giralt E. et al. (1995) Breast tumour response to primary chemotherapy predicts local and distant control as well as survival. Eur J Cancer 31A (12): 1969–1975.
81. Silver D.P. Richardson A.L. Eklund A.C. Wang Z.C. Szallasi Z. Li Q. et al. (2010) Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol 28: 1145–1153.
82. Sirohi B. Arnedos M. Popat S. Ashley S. Nerurkar A. Walsh G. et al. (2008) Platinum-based chemotherapy in triple-negative breast cancer. Ann Oncol 19: 1847–1852.
83. Tan A.R. Swain S.M. (2008) Therapeutic strategies for triple-negative breast cancer. Cancer J 14: 343–351.
84. Tan D.S. Marchio C. Jones R.L. Savage K. Smith I.E. Dowsett M. et al. (2008) Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients. Breast Cancer Res Treat 111: 27–44.
85. Tedesco K.L. Blum J.L. Goncalves A. Lubinski J. Ben-Baruch N. Osborne C.R. et al. (2010) A phase II trial of trabectedin (T) in patients (pts) with HER2-positive and BRCA1/2 germ-line-mutated metastatic breast cancer (MBC). J Clin Oncol 28(15 Suppl.): abstract 1038.
86. Turner N. Lambros M.B. Horlings H.M. Pearson A. Sharpe R. Natrajan R. et al. (2010) Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets. Oncogene 29: 2013–2023.
87. Turner N. Tutt A. Ashworth A. (2004) Hallmarks of ‘BRCAness’ in sporadic cancers. Nat Rev Cancer 4: 814–819.
88. Tursz T. Andre F. Lazar V. Lacroix L. Soria J.C. (2011) Implications of personalized medicine - perspective from a cancer center. Nat Rev Clin Oncol 8: 177–183.
89. Tutt A. Robson M. Garber J.E. Domchek S.M. Audeh M.W. Weitzel J.N. et al. (2010) Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA 1 or BRCA 2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 376: 235–244.
90. Verbeek B.S. Vroom T.M. Adriaansen-Slot S.S. Ottenhoff-Kalff A.E. Geertzema J.G. Hennipman A. et al. (1996) c-Src protein expression is increased in human breast cancer. An immunohistochemical and biochemical analysis. J Pathol 180: 383–388.
91. Viale G. Rotmensz N. Maisonneuve P. Bottiglieri L. Montagna E. Luini A. et al. (2009) Invasive ductal carcinoma of the breast with the “triple-negative” phenotype: prognostic implications of EGFR immunoreactivity. Breast Cancer Res Treat 116: 317–328.
92. Voduc D. Nielsen T.O. Cheang M.C. Foulkes W.D. (2008) The combination of high cyclin E and Skp 2 expression in breast cancer is associated with a poor prognosis and the basal phenotype. Hum Pathol 39: 1431–1437.
93. von Minckwitz G. Eidtmann H. Rezai M. Fasching P.A. Tesch H. Eggemann H. et al. (2012) Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med 366: 299–309.
94. Wang S. Shi Y. Yuan Z. Wang X. Liu D. Peng R. et al. (2011) Classical CMF regimen as adjuvant chemotherapy for triple-negative breast cancer may be more effective compared with anthracycline or taxane-based regimens. Med Oncol, in press.
95. Zabludoff S.D. Deng C. Grondine M.R. Sheehy A.M. Ashwell S. Caleb B.L. et al. (2008) AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies. Mol Cancer Ther 7: 2955–2966.
96. Zeng Q. Yang Z. Gao Y.J. Yuan H. Cui K. Shi Y. et al. (2010) Treating triple-negative breast cancer by a combination of rapamycin and cyclophosphamide: an in vivo bioluminescence imaging study. Eur J Cancer 46: 1132–1143.